Breda, the Netherlands/Ghent, Belgium –argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that following the implementation of the amended EU Transparency Directive (2013/50/EU), arGEN-X NV is required to publicly announce its Home Member State. In accordance with this regulation, the company announces that its Home Member State is the Netherlands.
